Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceuticals, Inc. Oncology Pharma will pursue the early feasibility and nonclinical development of a dactinomycin nanoemulsion drug product intended for the treatment of pediatric cancer.
加利福尼亞州舊金山/ACCESSWIRE/2021年8月19日/亞洲網加利福尼亞州米爾皮塔斯2月17日電腫瘤學制藥公司(場外交易代碼：ONPH)懷着萬眾期待，與NanoSmart製藥公司敲定了一項共同開發協議。腫瘤學制藥公司將致力於開發一種用於治療兒童癌症的放線菌素納米乳劑藥物產品的早期可行性和非臨牀開發。
Oncology Pharma is pleased to be moving forward with the development of its first product based upon licensed technology in Oncology Pharma's growing portfolio of licensed intellectual property. Oncology Pharma's agreement with NanoSmart Pharmaceuticals will allow for continued development of a proprietary lead-candidate formulation leading to the submission of an Investigational New Drug application to the US FDA. This phase of cancer drug development is intended to also support potential applications in veterinary oncology.
腫瘤學制藥公司很高興在腫瘤學制藥公司不斷增加的特許知識產權組合中，以特許技術為基礎開發其第一種產品。腫瘤學制藥公司與NanoSmart製藥公司達成的協議將允許繼續開發一種專利候選配方，從而向美國食品和藥物管理局提交一份研究用新葯申請。這一階段的抗癌藥物開發也旨在支持獸醫腫瘤學的潛在應用。
Oncology Pharma is excited to be combining efforts with NanoSmart Pharmaceuticals to pursue research and develop of improved treatments for pediatric cancers.
腫瘤學制藥公司很高興能與NanoSmart製藥公司共同努力，研究和開發兒童癌症的改進治療方法。
ABOUT ONCOLOGY PHARMA, INC.
腫瘤學制藥公司簡介
ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
腫瘤學制藥公司(Oncology Pharma，Inc.)OTCPK：ONPH)(“本公司”)目前正在從事腫瘤學療法的研究和開發，併為擁有一個世界級的顧問委員會而感到自豪，該委員會使本公司在癌症研究、生物技術和醫療保健領域的技術開發處於領先地位。
ABOUT NANOSMART PHARMACEUTICALS, INC.
Nanosmart製藥公司簡介
NanoSmart® Pharmaceuticals is a privately-held California corporation that is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to target existing drug therapies to areas of necrosis present in virtually all solid cancer tumors.
Nanosmart®PharmPharmticals是一傢俬人持股的加州公司，正在開發納米藥物輸送平台，包括利用抗核抗體(ANA)針對幾乎所有實體癌症腫瘤中存在的壞死區域進行現有藥物治療。
FORWARD LOOKING STATEMENTS
前瞻性陳述
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships, and costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
本公告中討論的某些事項包含前瞻性陳述，這些陳述涉及公司業務的重大風險和不確定性，可能導致實際結果與本文所作陳述預期的結果大不相同。這些風險和不確定因素包括與許可安排和合資企業有關的風險，包括需要就關係的最終協議進行談判；可能無法實現商業關係的預期利益，以及為這些商業關係提供資金的成本。與本公司有關的其他風險和不確定因素包括：當前運營現金流為負，需要額外資金為我們的運營計劃提供資金；任何進一步融資的條款，可能具有高度稀釋作用，可能包括苛刻的條款；意想不到的成本和運營赤字，以及低於預期的銷售和收入；客户採用新技術的意願和能力不確定，以及其他可能影響進一步市場接受度的因素；不利的經濟狀況；任何法律訴訟的不利結果；我們的經營業績和財務狀況的波動；無法吸引或留住合格的高級管理人員，包括銷售和市場營銷。我們通過專利過程建立和維護我們技術的專有性質的能力, 以及我們可能從其他公司獲得開發產品所需的專利和專利申請許可的能力；公司實施其技術各種應用的長期業務計劃的能力；公司與任何必要的營銷和/或分銷合作伙伴以及與任何戰略或合資夥伴簽訂協議的能力；競爭的影響；獲得和保持適用於公司技術應用的任何必要的監管許可；增長管理；以及其他風險和不確定因素。這不是買賣證券的徵集，也不是對公司財務狀況的分析。
CONTACTS:
聯繫人：
For additional Information, please contact the Oncology Pharma at:
如需更多信息，請聯繫腫瘤學制藥公司，網址為：
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
桑瑟姆街一號，套房3500加利福尼亞州舊金山，郵編：94104電話：415-869-1038傳真：415-946-8801網址：www.oncology-pharma.com電子郵件：info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
資料來源：腫瘤學制藥公司(Oncology Pharma Inc.)
譯文內容由第三人軟體翻譯。